GENE vs. ESLA, BCLI, INKT, PLUR, CRTX, SABS, ZIVO, EVAX, AIM, and PMCB
Should you be buying Genetic Technologies stock or one of its competitors? The main competitors of Genetic Technologies include Estrella Immunopharma (ESLA), Brainstorm Cell Therapeutics (BCLI), MiNK Therapeutics (INKT), Pluri (PLUR), Cortexyme (CRTX), SAB Biotherapeutics (SABS), ZIVO Bioscience (ZIVO), Evaxion Biotech A/S (EVAX), AIM ImmunoTech (AIM), and PharmaCyte Biotech (PMCB). These companies are all part of the "medical" sector.
Genetic Technologies (NASDAQ:GENE) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, community ranking, dividends, earnings and risk.
Estrella Immunopharma has lower revenue, but higher earnings than Genetic Technologies.
In the previous week, Genetic Technologies had 5 more articles in the media than Estrella Immunopharma. MarketBeat recorded 7 mentions for Genetic Technologies and 2 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.43 beat Genetic Technologies' score of 0.12 indicating that Estrella Immunopharma is being referred to more favorably in the news media.
Genetic Technologies has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, Estrella Immunopharma has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500.
Genetic Technologies received 161 more outperform votes than Estrella Immunopharma when rated by MarketBeat users.
0.6% of Genetic Technologies shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 6.5% of Genetic Technologies shares are held by insiders. Comparatively, 55.1% of Estrella Immunopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Genetic Technologies' return on equity of 0.00% beat Estrella Immunopharma's return on equity.
Summary
Genetic Technologies beats Estrella Immunopharma on 7 of the 10 factors compared between the two stocks.
Get Genetic Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for GENE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GENE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genetic Technologies Competitors List
Related Companies and Tools
